Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16550561 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5647446 | 0.91 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL16893568 | 0.91 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL27916634 | 0.91 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL16550581 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL19097646 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL19107464 | 0.86 | PTGS2 (0.90) | PTGS2PTGS1 | |
| SCHEMBL16707204 | 0.86 | PTGS2 (0.90) | PTGS2PTGS1 | |
| SCHEMBL19097644 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL16550632 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544356-B2 | Combination of a chromene compound and a second active agent | Euclises Pharmaceuticals, Inc. (US) | 2026-02-10 | — | — | US | claimed |
| CN-108779091-B | Combination of a chromene compound and a second active agent | 欧利瑟斯制药公司 | 2022-12-27 | — | — | CN | claimed |
| US-20220265602-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | Euclises Pharmaceuticals, Inc. | 2022-08-25 | — | — | US | claimed |
| US-20170196835-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | Euclises Pharmaceuticals, Inc. | 2017-07-13 | — | — | US | claimed |
| US-12544356-B2 | Combination of a chromene compound and a second active agent | Euclises Pharmaceuticals, Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| CN-108779091-B | Combination of a chromene compound and a second active agent | 欧利瑟斯制药公司 | 2022-12-27 | — | — | CN | disclosed |
| US-20220265602-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | Euclises Pharmaceuticals, Inc. | 2022-08-25 | — | — | US | disclosed |
| US-20170196835-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | Euclises Pharmaceuticals, Inc. | 2017-07-13 | — | — | US | disclosed |
| US-20170196835-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | Euclises Pharmaceuticals, Inc. | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544356-B2 | Combination of a chromene compound and a second active agent | CD274, ICOS, PDCD1 | PTGS2 2105/4885PTGS1 2633/4885 |
| US-20220265602-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | CD274, ICOS, PDCD1 | PTGS2 3149/4885PTGS1 2991/4885 |
| US-20170196835-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | CD274, ICOS, PDCD1 | PTGS2 3149/4885PTGS1 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.